AstraZeneca (AZN) to Release Quarterly Earnings on Thursday
AstraZeneca (NYSE:AZN) will be announcing its Q313 earnings results on Thursday, October 31st. Analysts expect the company to announce earnings of $1.27 per share and revenue of $6.45 billion for the quarter.
AstraZeneca (NYSE:AZN) last announced its earnings results on Thursday, August 1st. The company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.04. The company had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6.24 billion. During the same quarter in the previous year, the company posted $1.53 earnings per share. The company’s revenue for the quarter was down 6.4% on a year-over-year basis. On average, analysts expect AstraZeneca to post $5.15 EPS for the current fiscal year and $4.84 EPS for the next fiscal year.
Shares of AstraZeneca (NYSE:AZN) traded up 0.19% during mid-day trading on Wednesday, hitting $53.40. The stock had a trading volume of 1,353,394 shares. AstraZeneca has a one year low of $44.17 and a one year high of $53.45. The stock has a 50-day moving average of $50.19 and a 200-day moving average of $49.85. The company has a market cap of $66.857 billion and a price-to-earnings ratio of 13.60.
AZN has been the subject of a number of recent research reports. Analysts at Bank of America Corp. upgraded shares of AstraZeneca from an “underperform” rating to a “neutral” rating in a research note to investors on Monday. They now have a $55.20 price target on the stock, up previously from $48.82. On a related note, analysts at Jefferies Group downgraded shares of AstraZeneca from a “hold” rating to an “underperform” rating in a research note to investors on Friday, October 11th. Finally, analysts at Leerink Swann reiterated a “market perform” rating on shares of AstraZeneca in a research note to investors on Monday, September 30th. Five equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $53.73.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.